McGill University

Running trials

• Not yet recruiting

  A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).

  NCT07883590· Phase 1· Source

• Not yet recruiting

  Dialysis Less Frequently in the Elderly

  NCT07738731· Source

• Recruiting

  A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

  NCT07405801· Phase 2· Source

• Recruiting

  Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07491445· Phase 3· Source

• Recruiting

  Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

  NCT07154706· Phase 3· Source

• Active, not recruiting

  A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia

  NCT06953583· Phase 3· Source

• Recruiting

  A Study of Lorigerlimab in Participants With Advanced Solid Tumors

  NCT06730347· Phase 2· Source

• Recruiting

  Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

  NCT06801834· Phase 3· Source

• Enrolling by invitation

  Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0

  NCT06823115· Source

• Active, not recruiting

  Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

  NCT06578247· Phase 3· Source

• Not yet recruiting

  Pretreatment Botulinum Toxin in Head and Neck Cancer Surgery

  NCT06530524· Phase 2· Source

• Recruiting

  The diabEAT Study: Insulin dElivery Technologies And eaTing Behaviours in People With Type 1 Diabetes

  NCT07348432· Source

• Recruiting

  Fibrosis Lessens After Metabolic Surgery

  NCT06374875· Phase 4· Source

• Active, not recruiting

  MagDI Canada Study

  NCT06467955· Source

• Active, not recruiting

  [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer

  NCT06229366· Phase 1· Source

• Recruiting

  Using Micro-filaments to Detect "fast Ripples" and Improve the Identification of the Epileptogenic Zone

  NCT05254730· Source

• Active, not recruiting

  AMP SCZ® Observational Study: PREDICT-DPACC

  NCT05905003· Source

• Active, not recruiting

  Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease

  NCT05361382· Phase 1· Source

• Recruiting

  Parkinson's Foundation PD GENEration Genetic Registry

  NCT04994015· Source

• Recruiting

  PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

  NCT04477785· Source

• Active, not recruiting

  SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma

  NCT03546582· Phase 2· Source

• Recruiting

  International Severe Asthma Registry: Canadian Cohort

  NCT04045587· Source

• Recruiting

  Quebec Low Back Pain Study: Core Dataset

  NCT04791891· Source

• Enrolling by invitation

  North American Prodromal Synucleinopathy Consortium

  NCT03623672· Source

• Recruiting

  American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry

  NCT02674100· Source

• Active, not recruiting

  A Study for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

  NCT03127631· Source

• Active, not recruiting

  Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967· Phase 3· Source

• Active, not recruiting

  Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

  NCT01886872· Phase 3· Source

• Active, not recruiting

  Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

  NCT01522976· Phase 2· Source

• Active, not recruiting

  A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours

  NCT01396408· Phase 2· Source

• Active, not recruiting

  Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

  NCT01368588· Phase 3· Source

• Active, not recruiting

  Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

  NCT01274338· Phase 3· Source

• Active, not recruiting

  Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

  NCT01220583· Phase 2· Source

• Active, not recruiting

  RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

  NCT00956007· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease2 recruiting
• Lung cancer2 recruiting
• Pancreatic cancer2 recruiting
• Parkinson disease2 recruiting
• ALS (motor neurone disease)1 recruiting
• Asthma1 recruiting
• Endometrial cancer1 recruiting
• Epilepsy1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Head and neck cancer1 recruiting
• High blood pressure1 recruiting
• Lewy body dementia1 recruiting
• Metastatic breast cancer1 recruiting
• Obesity1 recruiting
• Ovarian cancer1 recruiting
• Type 1 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Petit Cactus Study

  NCT07380802· Source

• Completed

  Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

  NCT06667414· Source

• Completed

  A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes

  NCT05785832· Source

• Recruiting

  A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

  NCT04951622· Phase 3· Source

• Completed

  Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

  NCT03892096· Source

• Completed

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· Phase 3· Source

• Completed

  High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib

  NCT02551068· Source

• Completed

  A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion

  NCT02398656· Phase 3· Source

• Completed

  Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer

  NCT02254278· Phase 2· Source

• Completed

  LOWER: Lomitapide Observational Worldwide Evaluation Registry

  NCT02135705· Source

• Completed

  A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma

  NCT01650701· Phase 3· Source

• Completed

  S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer

  NCT01224665· Source

• Completed

  Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

  NCT00980954· Phase 3· Source

• Completed

  Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

  NCT00936390· Phase 3· Source

• Completed

  A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

  NCT00676715· Phase 2· Source

• Completed

  Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

  NCT00324805· Phase 3· Source

Trial sites

• McGill University32 trials
• McGill University Department of Oncology13 trials
• McGill University - Dept. Oncology1 trial
• McGill University - Dept. Oncology Clinical Research Program3 trials
• McGill University; Montreal Neurological Institute; Neurological and Psychiatric1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Alzheimer disease757 works · 1 trials
• Parkinson disease328 works · 3 trials
• Obesity172 works · 2 trials
• Prostate cancer149 works · 4 trials
• Ovarian cancer145 works · 1 trials
• Multiple sclerosis141 works · 1 trials
• Stroke128 works · 1 trials
• HIV115 works · 0 trials
• Schizophrenia108 works · 1 trials
• Type 2 diabetes95 works · 2 trials
• Epilepsy87 works · 1 trials
• Tuberculosis79 works · 0 trials
• Glioblastoma65 works · 0 trials
• Asthma60 works · 1 trials
• Melanoma59 works · 1 trials
• Atrial fibrillation53 works · 0 trials
• Bipolar disorder53 works · 0 trials
• Systemic sclerosis (scleroderma)50 works · 0 trials
• Depression47 works · 0 trials
• Type 1 diabetes45 works · 2 trials
• ALS (motor neurone disease)44 works · 1 trials
• Autism42 works · 0 trials
• Cervical cancer41 works · 1 trials
• Frontotemporal dementia41 works · 0 trials
• COPD38 works · 0 trials
• Endometrial cancer38 works · 1 trials
• Triple-negative breast cancer37 works · 1 trials
• Coronary artery disease35 works · 0 trials
• Ulcerative colitis35 works · 0 trials
• Crohn's disease33 works · 0 trials